Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors

Ajit G. Thomas, Camilo Rojas, Cordelle Tanega, Min Shen, Anton Simeonov, Matthew B. Boxer, Douglas S. Auld, Dana V. Ferraris, Takashi Tsukamoto, Barbara Slusher

Research output: Contribution to journalArticle

Abstract

Glutaminase catalyzes the hydrolysis of glutamine to glutamate and plays a central role in the proliferation of neoplastic cells via glutaminolysis, as well as in the generation of excitotoxic glutamate in central nervous system disorders such as HIV-associated dementia (HAD) and multiple sclerosis. Both glutaminase siRNA and glutaminase inhibition have been shown to be effective in in vitro models of cancer and HAD, suggesting a potential role for small molecule glutaminase inhibitors. However, there are no potent, selective inhibitors of glutaminase currently available. The two prototypical glutaminase inhibitors, BPTES and DON, are either insoluble or non-specific. In a search for more drug-like glutaminase inhibitors, we conducted a screen of 1280 in vivo active drugs (Library of Pharmacologically Active Compounds (LOPAC1280)) and identified ebselen, chelerythrine and (R)-apomorphine. The newly identified inhibitors exhibited 10 to 1500-fold greater affinities than DON and BPTES and over 100-fold increased efficiency of inhibition. Although non-selective, it is noteworthy that the affinity of ebselen for glutaminase is more potent than any other activity yet described. It is possible that the previously reported biological activity seen with these compounds is due, in part, to glutaminase inhibition. Ebselen, chelerythrine and apomorphine complement the armamentarium of compounds to explore the role of glutaminase in disease.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume438
Issue number2
DOIs
StatePublished - Aug 23 2013

Fingerprint

Glutaminase
Apomorphine
Kinetics
AIDS Dementia Complex
Glutamic Acid
chelerythrine
ebselen
Central Nervous System Diseases
Neurology
Bioactivity
Glutamine
Pharmaceutical Preparations
Small Interfering RNA
Multiple Sclerosis
Hydrolysis
Cell Proliferation

Keywords

  • Cancer
  • Glutamate
  • Glutaminase
  • Glutamine
  • HIV-associated dementia (HAD)
  • Kinetics

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. / Thomas, Ajit G.; Rojas, Camilo; Tanega, Cordelle; Shen, Min; Simeonov, Anton; Boxer, Matthew B.; Auld, Douglas S.; Ferraris, Dana V.; Tsukamoto, Takashi; Slusher, Barbara.

In: Biochemical and Biophysical Research Communications, Vol. 438, No. 2, 23.08.2013, p. 243-248.

Research output: Contribution to journalArticle

Thomas, Ajit G. ; Rojas, Camilo ; Tanega, Cordelle ; Shen, Min ; Simeonov, Anton ; Boxer, Matthew B. ; Auld, Douglas S. ; Ferraris, Dana V. ; Tsukamoto, Takashi ; Slusher, Barbara. / Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. In: Biochemical and Biophysical Research Communications. 2013 ; Vol. 438, No. 2. pp. 243-248.
@article{8b025942693a4bd4b00d29cdcad1a5fd,
title = "Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors",
abstract = "Glutaminase catalyzes the hydrolysis of glutamine to glutamate and plays a central role in the proliferation of neoplastic cells via glutaminolysis, as well as in the generation of excitotoxic glutamate in central nervous system disorders such as HIV-associated dementia (HAD) and multiple sclerosis. Both glutaminase siRNA and glutaminase inhibition have been shown to be effective in in vitro models of cancer and HAD, suggesting a potential role for small molecule glutaminase inhibitors. However, there are no potent, selective inhibitors of glutaminase currently available. The two prototypical glutaminase inhibitors, BPTES and DON, are either insoluble or non-specific. In a search for more drug-like glutaminase inhibitors, we conducted a screen of 1280 in vivo active drugs (Library of Pharmacologically Active Compounds (LOPAC1280)) and identified ebselen, chelerythrine and (R)-apomorphine. The newly identified inhibitors exhibited 10 to 1500-fold greater affinities than DON and BPTES and over 100-fold increased efficiency of inhibition. Although non-selective, it is noteworthy that the affinity of ebselen for glutaminase is more potent than any other activity yet described. It is possible that the previously reported biological activity seen with these compounds is due, in part, to glutaminase inhibition. Ebselen, chelerythrine and apomorphine complement the armamentarium of compounds to explore the role of glutaminase in disease.",
keywords = "Cancer, Glutamate, Glutaminase, Glutamine, HIV-associated dementia (HAD), Kinetics",
author = "Thomas, {Ajit G.} and Camilo Rojas and Cordelle Tanega and Min Shen and Anton Simeonov and Boxer, {Matthew B.} and Auld, {Douglas S.} and Ferraris, {Dana V.} and Takashi Tsukamoto and Barbara Slusher",
year = "2013",
month = "8",
day = "23",
doi = "10.1016/j.bbrc.2013.06.110",
language = "English (US)",
volume = "438",
pages = "243--248",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors

AU - Thomas, Ajit G.

AU - Rojas, Camilo

AU - Tanega, Cordelle

AU - Shen, Min

AU - Simeonov, Anton

AU - Boxer, Matthew B.

AU - Auld, Douglas S.

AU - Ferraris, Dana V.

AU - Tsukamoto, Takashi

AU - Slusher, Barbara

PY - 2013/8/23

Y1 - 2013/8/23

N2 - Glutaminase catalyzes the hydrolysis of glutamine to glutamate and plays a central role in the proliferation of neoplastic cells via glutaminolysis, as well as in the generation of excitotoxic glutamate in central nervous system disorders such as HIV-associated dementia (HAD) and multiple sclerosis. Both glutaminase siRNA and glutaminase inhibition have been shown to be effective in in vitro models of cancer and HAD, suggesting a potential role for small molecule glutaminase inhibitors. However, there are no potent, selective inhibitors of glutaminase currently available. The two prototypical glutaminase inhibitors, BPTES and DON, are either insoluble or non-specific. In a search for more drug-like glutaminase inhibitors, we conducted a screen of 1280 in vivo active drugs (Library of Pharmacologically Active Compounds (LOPAC1280)) and identified ebselen, chelerythrine and (R)-apomorphine. The newly identified inhibitors exhibited 10 to 1500-fold greater affinities than DON and BPTES and over 100-fold increased efficiency of inhibition. Although non-selective, it is noteworthy that the affinity of ebselen for glutaminase is more potent than any other activity yet described. It is possible that the previously reported biological activity seen with these compounds is due, in part, to glutaminase inhibition. Ebselen, chelerythrine and apomorphine complement the armamentarium of compounds to explore the role of glutaminase in disease.

AB - Glutaminase catalyzes the hydrolysis of glutamine to glutamate and plays a central role in the proliferation of neoplastic cells via glutaminolysis, as well as in the generation of excitotoxic glutamate in central nervous system disorders such as HIV-associated dementia (HAD) and multiple sclerosis. Both glutaminase siRNA and glutaminase inhibition have been shown to be effective in in vitro models of cancer and HAD, suggesting a potential role for small molecule glutaminase inhibitors. However, there are no potent, selective inhibitors of glutaminase currently available. The two prototypical glutaminase inhibitors, BPTES and DON, are either insoluble or non-specific. In a search for more drug-like glutaminase inhibitors, we conducted a screen of 1280 in vivo active drugs (Library of Pharmacologically Active Compounds (LOPAC1280)) and identified ebselen, chelerythrine and (R)-apomorphine. The newly identified inhibitors exhibited 10 to 1500-fold greater affinities than DON and BPTES and over 100-fold increased efficiency of inhibition. Although non-selective, it is noteworthy that the affinity of ebselen for glutaminase is more potent than any other activity yet described. It is possible that the previously reported biological activity seen with these compounds is due, in part, to glutaminase inhibition. Ebselen, chelerythrine and apomorphine complement the armamentarium of compounds to explore the role of glutaminase in disease.

KW - Cancer

KW - Glutamate

KW - Glutaminase

KW - Glutamine

KW - HIV-associated dementia (HAD)

KW - Kinetics

UR - http://www.scopus.com/inward/record.url?scp=84882662490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882662490&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2013.06.110

DO - 10.1016/j.bbrc.2013.06.110

M3 - Article

C2 - 23850693

AN - SCOPUS:84882662490

VL - 438

SP - 243

EP - 248

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -